During the past decade, Houston Institute for Clinical Research conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 19 clinical trials were completed, i.e. on average, 146.2% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 9 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Houston Institute for Clinical Research" #1 sponsor was "Pfizer" with 5 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Human Genome Sciences Inc." with 4 trials sponsored, "PLx Pharma" with 4 trials sponsored and "Bayer" with 4 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Houston Institute for Clinical Research" #1 collaborator was "GlaxoSmithKline" with 2 trials as a collaborator, "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)" with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "IQVIA Pvt. Ltd" with 1 trials as a collaborator and "OCT Clinical Trials" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Houston Institute for Clinical Research" are "Rheumatoid Arthritis" (10 trials), "Arthritis, Rheumatoid" (3 trials), "Systemic Lupus Erythematosus" (3 trials), "Acne Vulgaris" (2 trials) and "Osteoarthritis" (2 trials). Many other conditions were trialed in "Houston Institute for Clinical Research" in a lesser frequency.

Most popular intervention types in "Houston Institute for Clinical Research" are "Drug" (33 trials), "Other" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Methotrexate" (3 trials), "Tocilizumab" (3 trials), "Belimumab 1 mg/kg" (2 trials) and "Belimumab 10 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Houston Institute for Clinical Research" are 33 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Houston Institute for Clinical Research". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Houston Institute for Clinical Research, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Houston Institute for Clinical Research, 4 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".